Abstract
Objective: To evaluate whether the results of the first screening round in the Norwegian Breast Cancer Screening Program predict future mortality reduction and to explore the cost-effectiveness of the program.
Methods: The results of surrogate measures were calculated and compared with the targets. A cost-effectiveness analysis was performed assuming a nationwide program starting in 1996 with an attendance rate of 80% and a mortality reduction of 30%.
Results: The attendance rate was 79.5% and the detection rate was 0.67%. The proportion of invasive tumors smaller than 15 mm was 53.1%, and 21.7% of the patients who underwent axillary surgery had lymphatic metastasis. The C/E ratios were found to be 3750 US dollars (USD) per year of life saved and 86,045 USD per life saved.
Conclusion: The results of the first screening round will lead to a mortality reduction of at least 30%. The cost-effectiveness analysis shows that it is possible to run a highly cost-efficient screening program in Norway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nyström L, Rutquist LE, Wall S, et al. (1993) Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341: 974-978.
Tabár L, Fagerberg G, Duffy SW, Day N, Gad A, Gröntoft O (1992) Update of the Swedish two-county program of mammo-graphic screening for breast cancer. Radiol Clin N Am 30: 187-209.
Ottestad PM (1996) IT solutions in a centrally organised mammography screening in Norway. Medical Informatics Europe 34: 54-57.
Hervik A, Hagen KP, Nyborg K, Scheel HH, AÅvitsland G, Pettersen (1998) Nytte-kostnadsanalyser: Veiledning i bruk av lùnnsomhetsvurderinger i offentlig sektor. NOU 16 (in Norwegian).
Statistics Norway (1997) Fremskrivning av folkemengde 1996-2050 NOS: C4-4 (in Norwegian).
Engeland A, Haldorsen T, Tretli S, et al. (1993) Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS 101(Suppl. 30).
Engeland A, Haldorsen T, Tretli S, et al. (1995) Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010. APMIS 103(Suppl. 49).
Hristova L (1995) Evaluation of mortality reduction In: Effect of screening for Cancer on Mortality, Costs and Quality of Life in Finland. Acta Universitas Tamperensis ser A 456: 44-46.
Statistics Norway (1997) Offcial Statistics of Norway.
Bloom HGJ, Richardson WW (1957) Histologic grading and prognosis in breast cancer. Br J Cancer 11: 359-377.
Sjönell G, Ståhle L (1999) Há lsokontroller med mammografi minskar inte dö dlighet i bröstcancer (in Swedish). LaÈkartidningen 96: 904-913.
Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC (1999) The natural history of breast cancer. Cancer 86: 449-462.
de Wolf CJM, Perry NM (1996) European Guidelines for Quality Assurance in Mammography Screening. European Commission.
Lidbrink E, Tornberg SA, Azavedo EM, et al. (1994) The general mammography screening program in Stockholm. Acta Oncol 4: 353-358.
Lynge E (1998) Mammography screening for breast cancer in Copenhagen April 1991±March 1997. APMIS 106: 1-44.
Ekeberg Ø, Skjauff H, Kåresen R (2000) Screening for breast cancer is associated with a low degree of psychological distress. The Breast (in press).
Gram IT, Lund E, Slenker SE (1990) Quality of life following a false positive mammogram. Br J Cancer 62: 1018-1022.
Tabár L, Fagerberg G, Day N, Duffy SW, Kitchin RM (1992) Breast cancer treatment and natural history: new insights from results of screening. Lancet 339: 412-414.
Wang H, Jebsen P, Kåresen R, Thoresen Ø (2000) Ductal carcinoma in situ of the breast-a review of diagnosis, treatment and outcome in a hospital-based Norwegian series. Acta Oncol 39: 131-135.
Viscusi WK (1995) Discounting health effects for medical decisions. In: Sloane FA, ed. Valuing Health Care. Cambridge (UK): Cambridge University Press, pp. 125-144.
Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen O-P (1999) The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. Cancer 86: 638-646.
Tabár L, Fagerberg G, Duffy SW, Day N (1989) The Swedish two-county trial of mammography screening for breast cancer: recent results and calculation of benefit. J Epidemiol Commun Health 43: 114.
Koning Hd, Inenveld BM, Oortmarsen GJ, et al. (1995) Breast cancer screening and cost-effectiveness: policy alternatives, quality of life and the possible impact of uncertain factors. Int J Cancer 49: 531-537.
Nord E, Wislùff F, Hjorth M, Westin J (1997) Cost-utility analysis of melphalan plus prednisone with or without interferon-a2b in newly diagnosed multiple myeloma. Pharmacoeconomics 12: 89-103.
Wislùff F, Gulbrandsen N, Nord E (1999) Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. Pharmacoeconomics 16: 329-341.
Tengs TO, Adams ME, Pliskin JS, et al. (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 15: 369-390.
Elvik R (1993) ékonomisk verdsetting av velferdstap ved trafik-kulykker. Trafikk ékonomisk Institutt. 203 (in Norwegian).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wang, H., Kåresen, R., Hervik, A. et al. Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 12, 39–45 (2001). https://doi.org/10.1023/A:1008999403069
Issue Date:
DOI: https://doi.org/10.1023/A:1008999403069